Samsung Biologics reports third quarter 2024 financial results
Recorded Q3'24 consolidated revenue of KRW 1.2 trillionRecorded Q3'24 consolidated operating profit of KRW 338.6 billionContinued business expansion through strong competitive edge in speed and execution